FHTX at a glance
Foghorn Therapeutics Inc. (FHTX, SEC CIK 1822462) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 1, 2026 and Form 4 insider filings as recently as June 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Foghorn Therapeutics Inc. (FHTX) reported revenue of $30.9 million (up 36.8% from FY2024) and a net loss of $74.3 million. Diluted EPS was -$1.18.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Foghorn Therapeutics Inc. (FHTX) shares worth $75.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $30.9M
- +36.8% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $75.1M · +0 vs prior quarter
- Latest 8-K
- Oct 1, 2026
- Item 7.01 · Item 2.05
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Collaboration revenue $16.1M, up $8.5M YoY from $7.6M
- Net loss $7.2M versus $17.9M YoY; operating loss $8.8M versus $21.1M
- Best-performing revenue line: Lilly collaboration, driven by $14.2M cumulative catch-up adjustment
- R&D expense $18.5M, down $3.3M YoY; Lilly partnered programs declined $4.4M
- January 2026 offering generated $50.0M gross proceeds; additional funding required for ongoing operations
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- No newly added risk factor or quarter-specific trigger disclosed
- No regulatory, legal, or compliance risk updates disclosed
- No operational, competitive, market, liquidity, debt, currency, or concentration risk updates disclosed
AI summary of the FHTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Foghorn halted advancement of FHD-909 into the clinical trial expansion phase
- Strategic prioritization likely redirects resources toward other pipeline programs
Item 2.05: Costs Associated with Exit or Disposal Activities
- FHD-909 Phase 1 will not advance to expansion after clinical-data review
- Lilly collaboration activities no longer anticipated, removing a partnered development path
Item EX-99.1: Item EX-99.1
- Foghorn and Lilly will not advance FHD-909 after Phase 1 data failed to demonstrate sufficient efficacy
- Selective SMARCA2 degrader collaboration also ending, removing a partnered development path
Item 2.02: Results of Operations and Financial Condition
- Foghorn reported financial results for the quarter ended June 30, 2026
- Press release issued August 6, 2026; detailed figures provided in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- August 2026 investor presentation furnished as Exhibit 99.2 under Regulation FD
- Presentation likely contains updated investor-facing business, pipeline, or corporate information
Item EX-99.1: Item EX-99.1
- Q2 collaboration revenue $16.1M vs $7.6M, boosted by $14.2M cumulative catch-up tied to Lilly research-term expiration
- Net loss narrowed to $7.2M from $17.9M, while R&D fell to $18.5M from $21.8M
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders re-elected Douglas Cole, Simba Gill, and B. Lynne Parshall to three-year Class III terms ending at the 2029 annual meeting
- Deloitte & Touche LLP ratified as independent auditor for fiscal 2026, with 51,661,238 votes supporting
AI summaries of FHTX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for FHTX
Don't miss the next FHTX filing
- Alerts as it files. A push when FHTX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut FHTX, by share count.
- Ask anything. An AI agent that reads every FHTX filing and answers with sources.
FHTX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| SMITH IAN F | A | Jun 24, 2026 | 28,000 | $4.08 |
| Mendelsohn Michael | A | Jun 24, 2026 | 28,000 | $4.08 |
| Cole Douglas G. | A | Jun 24, 2026 | 28,000 | $4.08 |
| PARSHALL B LYNNE | A | Jun 24, 2026 | 28,000 | $4.08 |
| Duty Stuart | A | Jun 24, 2026 | 28,000 | $4.08 |
| Lynch Thomas J. Jr. | A | Jun 24, 2026 | 28,000 | $4.08 |
| Gallagher Neil | A | Jun 24, 2026 | 28,000 | $4.08 |
| Biller Scott | A | Jun 24, 2026 | 28,000 | $4.08 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $34.2M | $22.6M | $30.9M |
| Operating Income | - | -$102.7M | -$86.4M |
| Net Income | -$98.4M | -$86.6M | -$74.3M |
| Op. Margin | - | -454.3% | -279.5% |
| Net Margin | -288.2% | -383.2% | -240.3% |
| Balance Sheet | |||
| Total Assets | - | $284.0M | $198.1M |
| Equity | - | -$45.5M | -$108.5M |
| ROE | - | 190.3% | 68.5% |
| Per Share | |||
| EPS | $-2.34 | $-1.58 | $-1.18 |
| Cash Flow | |||
| Operating CF | - | -$100.4M | -$86.1M |
| CapEx | $1.2M | $906K | $50K |
Source: XBRL data in Foghorn Therapeutics Inc. (FHTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate FHTX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $75.1M |
| Q1 2026 | 23 | $73.2M |
| Q4 2025 | 22 | $80.3M |
| Q3 2025 | 20 | $69.3M |
| Q2 2025 | 20 | $65.1M |
| Q1 2025 | 17 | $41.3M |
| Q4 2024 | 12 | $52.4M |
| Q3 2024 | 10 | $14.6M |
- BlackRock+262.0K (+11%)
- Ameriprise Financial+109.7K (+24%)
- Invesco Ltd+60.4K (+341%)
- Vanguard Portfolio Management LLC+48.5K (+19%)
- Northern Trust+33.9K (+12%)
- FMR LLC (Fidelity)−341.2K (-6%)
- Raymond James Financial−112.4K (-4%)
- Citadel Advisors LLC−41.2K (-21%)
- Bank of America Corp−34.0K (-57%)
- Renaissance Technologies LLC−28.5K (-7%)
- Two Sigma Investments+12.4K
- Prudential Financial−12.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 147 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
FHTX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 1, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 21, 2026 | - | Analysis | - |
| 4 | Apr 13, 2026 | - | - | - |
| 10-K | Mar 11, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 11, 2026 | - | Analysis | - |
| 8-K | Feb 23, 2026 | - | Analysis | - |
| 4 | Feb 6, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
FHTX SEC filings: frequently asked questions
Which institutions hold FHTX stock?
As of June 30, 2026, the largest Foghorn Therapeutics Inc. (FHTX) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($27.8 million), BlackRock ($12.8 million), Raymond James Financial ($12.2 million), Vanguard Capital Management LLC ($7.3 million), State Street Corp ($3.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was FHTX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Foghorn Therapeutics Inc. (FHTX) reported revenue of $30.9 million (up 36.8% from FY2024) and a net loss of $74.3 million. Diluted EPS was -$1.18. The figures come from the XBRL data in the 10-K.
What did FHTX report in its latest 8-K?
Foghorn Therapeutics Inc. (FHTX) filed an 8-K on October 1, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.05 (Costs Associated with Exit or Disposal Activities). Foghorn halted advancement of FHD-909 into the clinical trial expansion phase.
What are the latest FHTX SEC filings?
Foghorn Therapeutics Inc. (FHTX) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 1, 2026 and a Form 4 insider filing on June 25, 2026.
What is FHTX's SEC CIK number?
Foghorn Therapeutics Inc. (FHTX)'s SEC Central Index Key (CIK) is 1822462. EDGAR lists every FHTX filing under that number.
Ask anything about FHTX
The research agent reads FHTX's filings, financials, insider trades and 13F holders, then answers with sources.